

Freedom of Information Request: Our Reference CTMUHB_397_23

You asked:

I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please answer the following question:

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

Our response:

Please see provided below a table populated with the data that Medicines Management are able to provide in relation to your enquiry. The period relates to the last 3 months available which is 1st June 2023 to 31st August 2023.

Medicine	Number of Patients
Adalimumab - Humira	**
Adalimumab Biosimilar	48
Apremilast	61
Bimekizumab	16

Croeso i chi gyfathrebu â'r bwrdd iechyd yn y Gymraeg neu'r Saesneg. Byddwn yn ymateb yn yr un iaith a ni fydd hyn yn arwain at oedi.

You are welcome to correspond with the health board in Welsh or English. We will respond accordingly and this will not delay the response.

Cyfeiriad Dychwelyd / Return Address:

Bwrdd Iechyd Prifysgol Cwm Taf Morgannwg, Pencadlys, Parc Navigation, Abercynon, CF45 4SN
Cwm Taf Morgannwg University Health Board, Headquarters, Navigation Park, Abercynon, CF45 4SN

Cadeirydd/Chair: Mr Jonathan Morgan

Prif Weithredydd/ Chief Executive: Mr Paul Mears

Bwrdd Iechyd Prifysgol Cwm Taf Morgannwg yw enw gweithredol Bwrdd Iechyd Lleol Prifysgol Cwm Taf Morgannwg
ICwm Taf Morgannwg University Health Board is the operational name of the Cwm Taf Morgannwg University Local Health Board

Brodalumab	5
Certolizumab	6
Deucravacitinib	0
Dimethyl fumarate	0
Etanercept - Enbrel	0
Etanercept Biosimilar	0
Guselkumab	30
Infliximab - Remicade	0
Infliximab Biosimilar	5
Ixekizumab	17
Risankizumab	50
Secukinumab	5
Tildrakizumab	13
Ustekinumab	35

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.